You are here: Industry Insights > Sanofi

News List

Philippine officials pull Dengvaxia's marketing license, but Sanofi asks them to reconsider fiercepharma
February 24, 2019
Sanofi set off an uproar in the Philippines with its 2017 disclosure that dengue shot Dengvaxia can cause more serious infections in some cases. Now, after investigations and more,?the country’s FDA has permanently revoked the vaccine’s marketing license.
Sanofi announces myeloma drug meets primary endpoint pharmaceutical-technology
February 19, 2019
French pharma giant Sanofi has unveiled that its multiple myeloma drug isatuximab has met its primary endpoint of prolonged progression-free survival in a Phase III trial.....
Jubilant Biosys expands collaboration with Sanofi for the CNS treatment area pharmafocusasia
February 15, 2019
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, today announced a new integrated collaboration with Sanofi for drug discovery for the CNS treatment area....
Sanofi Appoints Chief Digital Officer americanpharmaceuticalreview
February 13, 2019
Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer.....
Regeneron and Sanofi cut US list price of Praluent pharmaceutical-technology
February 13, 2019
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%....
Takeda’s dengue shot, rival to Sanofi's Dengvaxia, hits the mark in massive phase 3 study fiercepharma
January 30, 2019
It’s no secret Sanofi has had trouble with its world-first dengue vaccine, Dengvaxia, but that hasn't dissuaded Takeda. Its own dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.
NHS faces uphill battle in prevention – survey pharmaphorum
January 22, 2019
A new survey has revealed confusion amongst the UK public on how to maintain a healthy lifestyle, suggesting the NHS has a long way to go to meet its goal of more disease prevention.
Sanofi-Lexicon diabetes drug gets split verdict from FDA panel pharmaceutical-technology
January 21, 2019
Sanofi and Lexicon Pharmaceuticals have received split decision from an advisory panel to the US Food and Drug Administration (FDA) on whether to recommend diabetes drug Zynquista (sotagliflozin) for approval....
Sanofi and Biomunex partner to develop antibody therapeutics pharmaceutical-technology
January 17, 2019
Sanofi has signed a licensing agreement with French biopharmaceutical firm Biomunex Pharmaceuticals for the development of antibody-based drugs.....
Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies firstwordpharma
January 16, 2019
Biomunex will receive an initial upfront payment and will be eligible to receive further clinical, regulatory and commercial milestone payments. Further financial details were not disclosed.